Abstract:Background:The efficacy of standard triple therapy for eradication of Helicobacter pylori(Hp)is decreasing in recent years,and bismuth-containing quadruple regimen becomes the first-line therapy for Hp infection. However,the application of bismuth has some limitations. Aims:To investigate the efficacy of proton pump inhibitor(PPI)-based standard triple therapy combined with teprenone for Hp eradication. Methods:A total of 155 Hp-infected chronic gastritis patients were enrolled from Jan. 2013 to Dec. 2014 at Aerospace Center Hospital,and were randomly assigned into standard triple therapy group,bismuth-containing quadruple therapy group and teprenone-containing quadruple therapy group. Patients in standard triple therapy group were given rabeprazole sodium 20 mg + amoxicillin and clavulanate potassium 914 mg +clarithromycin 500 mg bid for 10 days. Patients in bismuth-containing quadruple therapy group were given standard triple therapy combined with bismuth potassium citrate 0. 6 g bid for 10 days. Patients in teprenone-containing quadruple therapy group were given standard triple therapy combined with teprenone 50 mg bid for 10 days. Symptoms of patients were evaluated before and after eradication therapy. Four weeks after the end of therapy,13 C-urea breath test( UBT)was reexamined to assess the status of Hp infection. Results:One hundred and fifty-two patients completed the treatment course. By ITT analysis,the eradication rates of standard triple therapy group,bismuth-containing quadruple therapy group and teprenone-containing quadruple therapy group were 69. 8%(37 / 53),86. 5% (45 / 52)and 88. 0% (44 / 50), respectively;by PP analysis,the eradication rates of the three groups were 71. 2%(37 / 52),88. 2% (45 / 51)and 89. 8%(44 / 49),respectively. Eradication rates analyzed by ITT and PP in bismuth-containing quadruple therapy group and teprenone-containing quadruple therapy group were significantly higher than those in standard triple therapy group(P <0. 05),but no statistically significant difference was found between these two groups( P > 0. 05). Relieving rates of abdominal pain,abdominal distention and belching in bismuth-containing quadruple therapy group and teprenone-containing quadruple therapy group were higher than those in standard triple therapy group,but statistically significant difference was only found in relieving of abdominal pain between teprenone-containing quadruple therapy group and standard triple therapy group(88. 9% vs. 70. 3% ,P < 0. 05). Adverse effects included transient and mild nausea,diarrhea and black stool, etc. Conclusions:Teprenone-containing quadruple regimen are effective for Hp eradication and symptoms relieving with no severe adverse effects,the efficacy is comparable with bismuth-containing quadruple regimen.

Rabeprazole Combined with Clarithromycin and Amoxicillin in the Treatment of Helicobacter Pylori-Related Ulcer

Polaprezinc Combined with Clarithromycin-Based Triple Therapy for Helicobacter Pylori-Associated Gastritis: A Prospective, Multicenter, Randomized Clinical Trial

Polaprezinc Combined with Triple Therapy for Helicobacter Pylori Associated Gastritis: A Prospective, Multicenter, Randomized Clinical Trial

Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-Positive Gastric Ulcer Patients after Eradication Therapy: A Randomized Double-Blind, Multinational, Multi-Institutional Comparative Study

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Long-term Therapeutic Effect of Triple Therapy Consisted of Omeperazole,clarithromycin and Amoxycillin in Children with Helicobacter Pylori Infection and Approach to Re-Treatment after Failure of the Treatment

The Symptomatic Improvement and Safety of Rabeprazole on Peptic Ulcer

Quadruple Therapy with Vonoprazan 20 Mg Daily As a First-Line Treatment for Helicobacter Pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial.

Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth‐containing quadruple therapy for Helicobacter pylori eradication in central China: A single‐center, prospective, open‐label, randomized‐controlled trial

[Dual Therapy with Rabeprazole and Amoxicillin Four Times Daily for 14 Days for the First-Line Eradication of Helicobacter Pylori Infection].

Pharmacogenetics of Esomeprazole or Rabeprazole-Based Triple Therapy in Helicobacter Pylori Eradication in Hong Kong Non-Ulcer Dyspepsia Chinese Subjects

Comparison of ranitidine bismuth citrate and lansoprazole-based regimens in the treatment of Helicobacter pylori infection

Meta-analysis of Esomeprazole-Based Triple Therapies in Helicobacter Pylori Eradication

Efficacy of Tetracycline-containing Triple Therapy for Eradication of Helicobacter pylori Infection

A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori

Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.

Comparison of efficacy of different treatment regimens on H.Pylori Eradication

Rabeprazole-Amoxicillin Dual Therapy As First-Line Treatment Forh Pylorieradication In Special Patients: A Retrospective, Real-Life Study

A Clinical Study of Proton Pump Inhibitor-containing Quadruple Regimen as First-line Therapy for Helicobacter pylori Eradication

Efficacy of PPI-based Standard Triple Therapy Combined with Teprenone for Treatment of Helicobacter pylori Infection

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori